Pharmacology and the treatment of complicated skin and skin-structure infections

New England Journal of Medicine

Volumn 370, Issue 23, 2014, Pages 2238-2239

  Chambers, Henry F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; LINEZOLID; ORITAVANCIN; VANCOMYCIN;

ALLERGIC REACTION; BACTERIAL SKIN DISEASE; CELLULITIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EDITORIAL; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SKIN ABSCESS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; FEMALE; GLYCOPEPTIDES; HUMANS; MALE; SKIN DISEASES, BACTERIAL; TEICOPLANIN; VANCOMYCIN;

EID: 84901776794     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1405078     Document Type: Editorial

References (8)

1. Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC Infect Dis 2013;13:252.
2. Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 2009;15:1516-8.
3. Dukic VM, Lauderdale DS, Wilder J, Daum RS, David MZ. Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis. PLoS One 2013;8(1):e52722.
4. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014;370:2169-79.
5. Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014;370:2180-90.
6. Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010;70:859-86. [Erratum, Drugs 2011;71:526.]
7. Ambrose PG, Drusano GL, Craig WA. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis 2012;54:Suppl 3:S220-S228.
8. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. Silver Spring, MD: Food and Drug Administration, 2013.